UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT00422422
- Locations
- 🇺🇸
113, Chesterfield, Missouri, United States
🇲🇽611, Chihuahua, Mexico
🇧🇪203, Brussels, Belgium
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00422110
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 228
- Registration Number
- NCT00419094
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 190
- Registration Number
- NCT00419393
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 159
- Registration Number
- NCT00401830
Effect of Brivaracetam in Photosensitive Epileptic Subjects
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT00401648
Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients
Completed
- Conditions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1000
- Registration Number
- NCT00394927
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT00389831
- Locations
- 🇩🇪
Schwarz BioSciences GmbH, Monheim, Germany
Study of Epratuzumab in Systemic Lupus Erythematosus
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 29
- Registration Number
- NCT00383513
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 54
- Registration Number
- NCT00383214
© Copyright 2024. All Rights Reserved by MedPath